S.E.E.D. Planning Group LLC Acquires 17,267 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• S.E.E.D. Planning Group LLC increased its holdings in Thermo Fisher Scientific by 157.3%, acquiring an additional 17,267 shares, bringing its total to 28,241 shares.
• Several brokerages recently adjusted their price targets for Thermo Fisher Scientific, with a consensus price target of $592.24 and recommendations ranging from "buy" to "hold".
• Insider transactions included the sale of shares by CAO Joseph R. Holmes and EVP Gianluca Pettiti, indicating increased insider selling activity.

S.E.E.D. Planning Group LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 157.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,241 shares of the medical research company's stock after buying an additional 17,267 shares during the quarter. Thermo Fisher Scientific accounts for about 3.6% of S.E.E.D. Planning Group LLC's investment portfolio, making the stock its 10th largest position. S.E.E.D. Planning Group LLC's holdings in Thermo Fisher Scientific were worth $11,451,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC grew its holdings in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after buying an additional 33 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at approximately $30,000. Finally, Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at approximately $31,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TMO. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. HSBC reissued a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. UBS Group lifted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. Seventeen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $592.24.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $479.48 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $181.06 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The business has a 50 day simple moving average of $466.86 and a 200 day simple moving average of $450.58.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the company earned $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.